Heart Institute uses advanced ablation technology for first time in Americas
Use of the VARIPULSE™ Platform marks a significant milestone in the treatment of atrial fibrillation.
- Research
International society recognizes Dr. Peter Liu as a pioneer in the field of heart failure
Dr. Peter Liu honoured with the Pioneer Award at annual scientific meeting of the Heart Failure Society of America
Annual Report 2023-24
In this annual report, we detail our progress in 2023-24 supporting our mission and vision for the future.
Heart Institute mourns the loss of Dr. Donald S. Beanlands
Dr. D. S. Beanlands presided over a golden age of growth in clinical care and training as the Heart Institute evolved in size and stature
- Research
Heart Institute scientist named to prestigious college of the Royal Society of Canada
Those named to the College represent the emerging generation of scholarly, artistic and scientific leadership in Canada
Canadian Cardiovascular Society bestows Heart Institute doctors with Recognition Awards
The Canadian Cardiovascular Society has awarded Dr. Jennifer Reed, Dr. Kwan-Leung Chan, and Dr. Christopher Johnson of the University of Ottawa Heart Institute with prestigious awards.
Smartphone app boosting emergency cardiac care efficiency
A secure, privacy-compliant point-of-care smartphone application is helping to reduce diagnostic time for patients in Ontario who may be experiencing a heart attack due to a blocked artery.
- Research
Heart Institute scientist to investigate differences between normal and diseased ventricular heart muscle
Dr. Kyoung-Han Kim will receive nearly one million dollars from the Canadian Institutes of Health Research Spring 2024 Project Grant Program
- Research
Heart Institute scientist appointed to expert panel to support and protect Canadian research data
Dr. Kelly Cobey will have the opportunity to shape evidence-based policy in Canada
Heart Institute first in North America to implant advanced bicaval valve system in patient
The Tricvalve® Transcatheter Bicaval Valve System is designed for the treatment of patients with severe tricuspid insufficiency, a form of valvular heart disease